טוען...
The Patient Journey with PCSK9 Inhibitors in Community Practice
BACKGROUND: Trials have demonstrated that proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are effective as an adjunct to statin therapy, but access and cost issues have limited their use in community practice. OBJECTIVE: To better understand patients’ experiences when trying to obta...
שמור ב:
| הוצא לאור ב: | J Clin Lipidol |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7376543/ https://ncbi.nlm.nih.gov/pubmed/31371271 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jacl.2019.06.008 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|